Skip to main content

MSOS

ETF

Performance overview

MSOS Price
Price Chart

Forward-looking statistics

Beta
0.88
Risk
74.57%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Fund Profile

The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from the marijuana and hemp business in the United States and in derivatives that have economic characteristics similar to such securities. It will concentrate at least 25% of its investments in the pharmaceuticals, biotechnology & life sciences industry group within the health care sector. The fund is non-diversified.

Fund info

The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from the marijuana and hemp business in the United States and in derivatives that have economic characteristics similar to such securities. It will concentrate at least 25% of its investments in the pharmaceuticals, biotechnology & life sciences industry group within the health care sector. The fund is non-diversified.

Investing methodActively Managed
DiversifiedYes
Expense ratio0.75%
Asset classUnknown

Company info

Sector
Industry
Website
AUM

Security info

ExchangeNyse American
Type of shareN/A
Earnings per share (EPS)
Dividend per share
Revenue per share
Avg trading volume (30 day)$11M
Avg trading volume (10 day)$11M
Put-call ratioN/A

Macro factor sensitivity

Growth-6.3
Credit+8.2
Liquidity+5.3
Inflation-9.8
Commodities-2.5
Interest Rates-1.3

Upcoming events

Next earnings day
Next dividend day
Ex. dividend dayDecember 23, 2021

News

Best-Performing ETF Areas of Last Week

Trump's sweeping new tariffs on Canada, the EU, and Mexico weight on markets slightly last week. However, crypto (i.e.

Zacks Investment Research (July 15, 2025)
Hedge Fund Veteran Doug Kass Says Most Cannabis Stocks Are 'Walking Dead,' But These 4 Names Stand Out

Veteran hedge fund manager Doug Kass isn't mincing words about the state of the cannabis industry. In a recent column titled 'Picking the Cannabis Winners in an Industry Full of the Walking Dead,' the Seabreeze Partners president outlined why he believes most public cannabis companies are distressed and structurally unsound — but also identified a small group he still considers investable.

Benzinga (May 15, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free